Immunotherapy and impact on tissue reservoirs.

Area of Science:

• Immunology
• Virology
• Neuroscience

Background:

• Human Immunodeficiency Virus (HIV) establishes reservoirs across various body tissues, complicating eradication efforts.
• Effective HIV cure strategies must address both peripheral blood and tissue-based viral reservoirs.
• Immune-privileged sites, such as the central nervous system (CNS), present unique challenges for HIV reservoir targeting.

Purpose of the Study:

• To review recent immunotherapy approaches for HIV cure.
• To evaluate the efficacy of these immunotherapies in targeting viral tissue reservoirs.
• To assess the penetration of immunotherapies into immune-privileged sites like the CNS.

Main Methods:

• Review of recent clinical trials and immunotherapy strategies for HIV cure.
• Analysis of T cell therapies, including chimeric antigen receptor (CAR) T cells.
• Evaluation of monoclonal antibody therapies and immune checkpoint inhibitors.
• Assessment of the ability of these therapies to penetrate the CNS.

Main Results:

• Immunotherapy clinical trials have shown viral control in some participants.
• T cell therapies (e.g., CAR T cells) and broadly neutralizing antibodies show promise.
• Immune checkpoint inhibitors can enhance immune function against HIV.
• Limited CNS penetration of many immunotherapies remains a significant barrier.

Conclusions:

• Immunotherapies offer a promising avenue for HIV cure, but targeting tissue reservoirs is a major hurdle.
• Combination approaches using multiple immunotherapy strategies are likely necessary.
• Developing strategies to overcome CNS penetration barriers is crucial for widespread success in achieving an HIV cure without antiretroviral therapy.